Target to Treatment is an independent consultancy specialising in early drug discovery and development.
Target to Treatment Consulting Ltd is an independent consulting firm that provides services to Academic Institutions, BioTech companies and Big Pharma. We are experts in enhancing and optimising early drug discovery and development from candidate selection through First-in-human trials to clinical proof-of-concept (Phase 2A). We specialise in several therapy areas e.g. fibrosis, immuno-oncology, inflammation, tuberculosis, rare diseases, infectious diseases, auto-immunity and COVID-19. Get in touch for an initial discussion.
End-to-End Planning • Medicine vision • Clinical development planning • Orphan drug Designation • Breakthrough status • Novel endpoints for innovative clinical trials • Translation: mouse-to-man (Target-to-Treatment) • Dialogue with Regulators • Dose prediction • First-in-human trials • Clinical Proof-of-concept • Risk/benefit analysis • Mitigation of risk • Indication prioritisation • Question-based clinical development • Biomarker identification and implementation • Molecular imaging
“We couldn't have developed the project without your input."
“A big thank you for all your work on both trial protocols, it really has been appreciated and your insights have proven invaluable, especially
on the end points and your work with the statisticians for both trials.
You spotted many key things that ultimately helped design the 2 trials that we believe will have the most significant impact on our company.”
“Thank you so much for a fantastic workshop today! You could see from all the questions the level of engagement that you got from our start-ups, and I know they will have found that session hugely useful!”
"The quality of the work that has been done is outstanding, and it is a great pleasure working with such a skilled, professional consultant.”
Orphan Drug Designation (ODD in EU and US), regulatory buy-in on clinical trial design, optimal dose selection, biomarker decision-making and other successful interactions with regulators.
Chemical entities and biologicals, targeting a variety of mechanisms from candidate selection to clinical proof of concept. The medicine vision (clear evidence of differentiation), delivering the clinical plan (accountable for over 20 clinical studies) and achieving key milestones on time and in budget.
Building platforms to enable decision-making during clinical development using novel endpoints, e.g. imaging, biomarkers and ‘omics approaches.
In vitro and in vivo models that enable decision-making for candidate selection, development of pharmacodynamic markers and proof of mechanism.
Alignment of project and business objectives in order to ensure availability of budget and support for project plans.
Disease areas covered: fibrosis (emphasis on pulmonary fibrosis), immuno- inflammation (emphasis on rheumatoid arthritis), infectious diseases (emphasis on tuberculosis), rare diseases (osteogenesis imperfecta) and oncology (AML and breast cancer).
Pauline T. Lukey
(Bsc Hons, Msc, PhD)
Founder & Managing Director
Pauline is a Drug Discovery and Development professional with decades of experience in Pharma, Biotech and Academia. She is currently working as an independent consultant for a variety of clients, covering all aspects of the pipeline from the selection of a candidate molecule, through Translational Science, First in Man up to and including Clinical Proof of Concept (PoC). On behalf of her clients, she has successfully obtained Orphan drug status in the EU and US, breakthrough designation and accelerated approvals amongst others. She led a variety of projects over 20 years at GlaxoSmithKline R&D, moving both small molecules and biologicals, from candidate to PoC (representing design and delivery of over 20 individual clinical trials). She has extensive experience in various therapy areas: Fibrosis, inflammation, autoimmunity, rare diseases, immune-oncology. In addition, she lectures to the postgraduate students in Immunology at the London School of Hygiene and Tropical Medicine, she is on the Strategic Advisory Board for the Engineering and Physical Science Research Council’s (EPSRC) Prosperity Partnership (AI/ML to expedite clinical development) and has published over 60 articles in peer reviewed journals.
Her interests include: Family, travelling, reading, cooking, eating, drinking and being merry.
David C. Lukey
(BA Hons, MB BCh, MBA)
David is a results-driven management professional with over 13 years of business leadership and consultancy experience and 20 years of experience as a general medical practitioner. Innovative strategist, developing and implementing cutting-edge solutions to drive revenue growth, optimise services, and move organisations forward. Dynamic leader, training and motivating people to deliver top performances. Offering extensive medical expertise and pharmaceutical knowledge, with robust industry network. Proven track record of initiating and steering visionary projects that drive success. Areas of proficiency include: Business Management, Business Development, Strategic Analysis/Planning , Revenue Generation, Project Management, Medical/Pharmaceutical Writing, HR Managemen, Operations, Networking, Client Relationships, Leadership, Training/Mentoring, Medical/Pharma Expertise .
He is married with two adult sons and enjoys photography in his spare time.
Victoria joined Target to Treatment in 2019. She provides administrative support to the company, sending out invoices and responding to company emails. She has a BA in Graphic Design which she uses to develop the company branding, as well as infographics for clinical studies.
(BA Hons, MSci, PhD)
Callum joined Target to Treatment Consulting Ltd as a Research Associate in 2022 where he works across the range of our client services. Having developed his scientific skills during his time as a PhD student and subsequently working at the MRC Cancer Unit in the University of Cambridge, he has extensive experience with cell and cancer biology and data analysis.
He is looking forward to applying these skills to working in the pharmaceutical industry.